Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
Hosted on MSN
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids, Tuberculosis, ...
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On November 24, Truist’s ...
Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho ...
News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...
Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...
HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can negatively impact patients and their treatment. Now lessons learned from the HIV ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback